Compare Hewlett Packard Enterprise Co (HPE) vs Summit Therapeutics Inc (SMMT) Price & Performance

HPE trades at $46.73, up 1.99% today, with a bullish technical signal and strong recent earnings beats. The stock is supported by a $6.3 billion AI backlog and a strategic shift toward high-margin networking, which now drives 44% of segment profit. Revenue grew to $34.3 billion in 2025, though net income fell sharply to $57 million due to heavy investment. Analysts maintain a consensus price target of $69.69, implying significant upside.

Outlook is positive given AI infrastructure demand and networking momentum, but risks include execution on large investments, competitive pressures, and volatile cash flows. The stock offers growth potential if margin expansion continues, yet investors must monitor debt levels and earnings consistency amid macroeconomic uncertainty.

Summit Therapeutics (SMMT) trades at $13.50, down 2.24% on the day, reflecting a bearish technical trend amid negative profitability. The company reported a net loss of $1.08 billion for 2025, with deeply negative ROE and ROA, though a recent asset sale and positive clinical trial data for its oncology candidate provide some operational catalysts. Cash flow remains volatile, with net cash flow turning negative in 2026 projections.

The investment case is binary, hinging on the success of ivonescimab. While analyst consensus is bullish with a $15.57 price target, high volatility and ongoing fiduciary investigations pose significant risks. The stock offers high-reward potential for risk-tolerant investors betting on clinical success, but fundamental weaknesses and cash burn necessitate caution.